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Novel 3D imaging 
platform tracks cancer 
progression in vivo
for preclinical readouts of disease remains histopathology, 
where the animal is sacrificed and tissue sections produced 
from regions of interest are stained and imaged at high 
resolution using optical microscopy. Unfortunately, this 
can only be performed at a single timepoint per animal and, 
because only a finite number of sections can be produced, 
the volumetric sampling may miss important features in 
heterogeneous tissue. Furthermore, the whole process is 
time-consuming, requiring significant manual processing 
and the small fields of view typical of microscopy must 
be stitched together to map significant fractions of the 
animal. Fluorescence microscopy can be implemented 
directly in vivo but the limited field of view and the 
strong absorption and optical scattering experienced by 
light in tissue limits the range of physiological contexts 
that can be accessed. Furthermore, the process usually 
involves invasive procedures with animals that must be 
euthanized. Currently therefore, whole-animal preclinical 
imaging in mammals mainly relies on modalities like 
X-ray computed tomography (CT), magnetic resonance 
imaging and positron emission tomography, which 
cannot realize the high (cellular) resolution or molecular 
contrast and specificity that are available with fluorescence 
imaging. Fluorescence imaging in intact mice can be 
James McGinty,   
Paul French (Imperial 
College London, UK) and 
Paul Frankel (University 
College London, UK))
The rise of fluorescent proteins
The development of target-specific labelling strategies 
– particularly the ability to express genetically encoded 
fluorescent proteins in live cells1 – has enabled cellular 
processes and signalling pathways to be visualized and 
quantified. For convenience, such studies are usually 
undertaken in thin cell cultures (typically on microscope 
coverslips), but there is an increasing appreciation that 
the behaviours observed in 2D cell mono-cultures cannot 
necessarily be directly translated into an in vivo context2. This 
is particularly important for understanding disease processes 
and determining the efficacy, safety and off-target effects of 
therapies in the drug discovery pipeline. Subsequently, there 
has been a drive to develop imaging techniques and assays 
to study disease mechanisms in more realistic physiological 
contexts. Ideally, preclinical studies should be undertaken 
in disease models that are as close to humans as possible. 
However, this aspiration is set against the ability to genetically 
manipulate the organisms and considerations of accessibility 
for optical and other readouts. 
Murine models are widely used because of their 
genetic tractability and physiological similarity to humans 
but they are not optically accessible and the gold standard 
Optical imaging underpins biomedical research in many respects and recent decades have seen spectacular 
advances, particularly in fluorescence imaging where genetic engineering approaches to labelling have 
been combined with new light sources, detectors and data analysis techniques to provide capabilities like 
super-resolution beyond the diffraction limit, exquisite spectroscopic contrast for molecular readouts and 
high-speed image capture for in vivo and high-throughput applications. However, the main impact of such 
advanced instrumentation and data analysis has been to provide unprecedented quantitative 2D and 
3D information concerning samples compatible with microscopy where volumes of less than 1 mm3 are 
typically imaged in a single ‘acquisition’. The ability to view and measure cellular processes and signalling 
pathways in live cells has been a significant advance for biomedical research and drug discovery. However, 
for conventional microscope-based assays and experiments, the samples typically comprise thin layers of 
cells that are not experiencing the same signals that they would in a 3D tissue context and any findings 
may not directly translate to live organisms. It is desirable to study disease processes in live intact organisms 
that can provide appropriate physiological complexity. For cancer studies, recent research from our group 
shows that optical tomography can be used to directly monitor in vivo changes in tumour growth and 
vascular development in a zebrafish cancer model over time. This technique not only improves the value of 
the collected data, but if used on a wider scale should result in a reduction in the number of animals used 
in biomedical research. 
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realized using fluorescence molecular tomography 
and similar techniques3 that essentially consider the 
statistical properties of light transport in biological tissue 
and usually rely on simplifying assumptions to analyse 
signals based on scattered photons, such as the diffusion 
approximation. These approaches can reconstruct maps 
of the tissue’s optical properties using inverse scattering 
techniques, but produce images with  spatial resolution 
limited to greater than 1 mm in mice – significantly 
degraded compared with the optical diffraction limit. 
Potential of in vivo optical imaging
Higher resolution in vivo optical imaging is possible in 
smaller transparent organisms such as the nematode 
worm (Caenorhabditis elegans), fruit fly (Drosophila 
melanogaster) and larvae of fish such as the zebrafish 
embryo (Danio rerio), that typically entail imaging through 
a path of less than 1 mm and for which the usual range 
of genetic tools are available. This regime is described 
as ‘mesoscopic’ imaging and is a very active field that 
encompasses techniques such as optical projection 
tomography (OPT)4 and light sheet microscopy5, which 
can provide high-speed, high-resolution 3D imaging for 
volumes up to ~1 mm in size. While nematodes and flies 
are non-vertebrates, zebrafish physiology is closer to that of 
humans and zebrafish larvae are finding increasing interest 
as a convenient disease model for biomedical research 
and drug discovery6. However, limiting the application 
of zebrafish studies to embryos also limits the research 
opportunities, as the larvae are physiologically immature 
and do not possess fully developed body systems, such as 
vasculature and immune systems. In this respect, studies 
using adult zebrafish models are more desirable. However, 
adult zebrafish reach up to ~1 cm in diameter and ~5 cm 
in length and so are too large for whole-body imaging in 
a microscope. Furthermore, whereas zebrafish larvae can 
be kept optically clear, wild-type zebrafish are pigmented 
– resulting in significant optical scattering and absorption. 
The use of zebrafish as in vivo models to study cancer 
is increasing as they possess various advantages over their 
mouse counterparts such as easier genetic manipulation 
and a broader range of imaging opportunities with 
transparent lines. In relation to translational research, the 
histological appearance and gene expression profiles of 
tumours have been shown to be highly conserved between 
humans and zebrafish7. Such histological and genetic 
similarities suggest that pathogenesis is similar between 
these species, thus validating the use of these organisms as 
faithful cancer models. 
We have developed a whole-animal 3D optical imaging 
platform that takes advantage of non-pigmented zebrafish 
mutants, of which the adults are sufficiently transparent 
to permit optical readouts8,9,10. This platform is based on 
OPT of adult fish that are immobilized under anaesthetic 
Figure 1. Schematic of an OPT system. 
and utilizes a compressive sensing approach10 to minimize 
the data acquisition time and therefore enables the fish to 
be recovered and reimaged over an extended time course 
for longitudinal studies11. 
Optical projection tomography  
of live zebrafish
OPT can be described as the optical equivalent of X-ray 
CT. It entails rotating the sample and acquiring a series 
of wide-field fluorescence images at a number of different 
angular projections, as illustrated in Figure 1. The sample 
is suspended from a rotation stage in a chamber of 
refractive index matching fluid (for in vivo imaging this 
is just water). Appropriate excitation light illuminates the 
sample (in wide-field) to generate fluorescence, which is 
imaged onto a camera using an imaging system with an 
aperture. The radius of this aperture is set such that the 
front half of the sample is imaged ‘in focus’, providing a 
projection image. The sample is then sequentially rotated 
and imaged at a range of angles until it has stepped 
through a full 360° rotation. 
Following the standard formalism of CT12, each pixel 
in the wide-field fluorescence image can be considered as 
the sum of the fluorescence signal along a ‘line-of-sight’ 
perpendicular to the camera sensor – or in other words, the 
2D wide-field image is a ‘projection’ of the 3D fluorescent 
volume. This is analogous to an X-ray image containing 
information about the absorption of a 3D sample along 
‘lines-of-sight’ and the acquisition and reconstruction 
procedure are equivalent to X-ray CT: the 3D fluorescence 
image is reconstructed from the set of angular projection 
images using filtered backprojection (FBP). An important 
assumption for FBP, as in X-ray CT, is that the detected light 
has travelled in straight lines from the sample to the detector, 
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we applied a compressed sensing approach where we 
acquired only 64 angular projections for each OPT data 
set (rather than the ~600 projections required for lossless 
reconstruction using standard FBP) and reconstructed 
the images iteratively as described in 10. 
To validate our platform, we performed a cross-
sectional study of tumour progression over 3 weeks 
followed by 1 week without inducer, which results in 
tumour regression. Typical segmented reconstructed 
tomographic images acquired over this time course of 
tumour (green) and vasculature (red) are shown in Figure 
2(a). Tumour and segmented vasculature 3D images were 
then analysed in terms of tumour volume and vessel 
properties (e.g. branching, average vessel length, tortuosity, 
etc.11). Figure 2(b,c) show quantitative measurements of 
tumour progression and vascularization derived from 
the 3D reconstructions of the in vivo OPT acquired 
data. Figure 2(d) shows the corresponding changes in 
vascularization measured using immunohistochemistry. 
Importantly, the similarities observed in the comparative 
analysis of OPT vs immunohistochemistry of the tumour 
vasculature validates our approach. 
Since OPT data acquisition is non-invasive, it does 
not require the zebrafish to be sacrificed and so repeated 
measurements can be undertaken for longitudinal 
studies. Importantly, the OPT data is whole-body 
and not limited to discrete spatial sampling, unlike 
histopathology. This means that OPT could potentially 
readout non-local effects/structures like metastasis, 
which would require significantly more pathological 
analysis and/or would otherwise be missed.
therefore the light should not have been scattered and the 
sample being imaged should lie within the depth of field of 
the imaging lens. The requirement for the sample to be non-
scattering means that OPT has typically been used to image 
‘chemically cleared’ samples4, for which water in the sample 
has been replaced by a liquid of higher refractive index in 
order to minimize the refractive index variation between 
different tissue components and therefore to minimize 
optical scattering. Since this chemical treatment can only be 
performed ex vivo on fixed samples, it is necessary to realize 
in vivo OPT with transparent organisms. As discussed above, 
we have established that non-pigmented adult zebrafish 
mutations are sufficiently transparent to enable OPT to be 
performed in vivo on anaesthetized samples. 
Imaging tumour growth  
and vascularization
Figure 2 illustrates how whole-body OPT of a zebrafish 
cancer model can enable tumour growth and vasculature 
to be studied. We imaged ‘transparent’ zebrafish in which 
the growth of a liver tumour expressing green fluorescence 
protein could be prompted by exposure to a chemical 
inducer10. This disease model also expresses mCherry 
fluorescence protein in the endothelial cells of the blood 
vessels. By mapping the 3D distribution of green and 
red fluorescence in these fish through in vivo OPT, we 
could measure tumour and vasculature development in 
a minimally invasive way, requiring less than 10 minutes 
to acquire the data in both red and green fluorescence 
channels. To acquire the image data in such a short time 
Figure 2. (a) segmented reconstruction of in vivo OPT data with tumour (green) and vasculature (red), and plots showing (b) tumour volume and (c) % 
tumour vascularization determined from the in vivo OPT data and (d) measurements based on ex vivo immunohistochemistry. Each point is an individual 
fish. Scale bar 5 mm. 
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Future directions
This initial study demonstrated that in vivo OPT can 
be used to monitor vascular changes associated with 
tumour growth/recession in live adult zebrafish with 
similar quantitative readouts to those obtained from 
histopathological assessment. Unlike histopathology, 
however, OPT interrogates the whole zebrafish and 
permits longitudinal studies. This will lead to improved 
data consistency by reducing the impact of biological 
variability between different fish. In turn, this can lead 
to a reduction in the total number of zebrafish required 
to produce statistically significant readouts for assays of 
cancer progression and the response to potential therapies. 
Our study11 was limited to fluorescence intensity 
imaging but more sophisticated fluorescence imaging 
techniques, such as spectrally and lifetime-resolved 
fluorescence imaging applied in microscopy, can also be 
implemented with OPT. For example, we have demonstrated 
that Fluorescence Lifetime Imaging Microscopy (FLIM) 
OPT can be applied to provide 3D quantitative readouts 
of genetically expressed Förster resonance energy transfer 
(FRET) biosensors, specifically mapping radiation-induced 
apoptosis in zebrafish embryos using FLIM OPT of a FRET 
biosensor for caspase 313. 
We believe that this work illustrates how the 
combination of semi-transparent model organisms that 
can be genetically manipulated with whole-body 3D 
imaging techniques can be used for both fundamental 
biology and drug discovery and efficacy studies. It 
can take advantage of the significant developments 
made in fluorescent reporters developed for cellular 
assays, transferring them to in vivo assays, including 
longitudinal studies with the potential to improve data 
consistency and reduce the numbers of animals required 
for biomedical research and drug discovery.  ■
This work was primarily supported by the UK Medical 
Research Council with contributions from the British Heart 
Foundation, the UK Engineering and Physical Sciences 
Research Council, the National Institute for Health 
Research, the Brain Tumour Charity (UK), AstraZeneca and 
Magnus Life Science. 
James McGinty is a Senior Lecturer in 
the Department of Physics at Imperial 
College London. His initial research 
career concentrated on developing 
instrumentation and analysis software for 
time-resolved fluorescence imaging with 
particular emphasis on fast acquisition rates. His current research 
concentrates on translating and applying quantitative microscopy 
techniques to more challenging and/or physiologically relevant 3D 
samples, including cm-sized resected tissue volumes, zebrafish and 
mice. Maintaining the same optical contrast mechanism across the 
imaging scales should lead to improved correlation between initial 
in vitro cell and subsequent in vivo measurements.
Paul French is Professor of Physics and 
former Head of the Photonics Group at 
Imperial College London. He has also 
worked at the University of New Mexico 
and AT&T Bell Laboratories. His research 
has evolved from ultrafast dye and 
solid-state laser physics to biomedical optics with a particular 
emphasis on FLIM for applications in molecular cell biology, 
drug discovery and clinical diagnosis. His current portfolio 
includes the development and application of multidimensional 
fluorescence imaging technology for microscopy, endoscopy 
and tomography.
Dr Paul Frankel is a Group Leader in the 
Division of Medicine at University College 
London and a consultant for Magnus Life 
Sciences. His research specialises in the 
development of novel molecular targeted 
agents for the treatment of cancer. Dr 
Frankel received a PhD in Molecular Biology from the City 
University of New York Hunter College, specialising in cancer cell 
signalling. He then moved to the UK to undertake post-doctoral 
studies in the Laboratory of Professor Chris Marshall FRS at 
The Institute of Cance Research. Dr Frankel’s group combine 
molecular analysis of cell signalling required for cancer cell 
motility with state-of-the-art 3D imaging technologies and are 
working on multiple drug discovery activities.
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